KRIVOX INC. — SEC Form D Filing

KRIVOX INC. filed an SEC Form D on May 12, 2026, reporting $300K raised in Healthcare Technology.

Form D filing details

Filing
SEC Form D
Filing date
May 12, 2026
Amount reported
$300K
Round stage
Pre-Seed
Industry
Healthcare Technology
Website
https://krivox.io/

What the company does

Securities: SAFE. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients in emerging markets often lack structured access to specialist medical opinions, relying on fragmented and inconsistent pathways.

Solution

Krivox provides a cross-border advisory platform called Apex Opinion that connects patients with vetted US board-certified specialists, offering secure access to second opinions on complex medical cases typically within 5 to 7 business days.

Why now

There is a growing need for structured access to specialist medical consultations across international borders, especially in emerging markets.

Verdict

Investors likely said yes to Krivox because the allure of telehealth solutions in emerging markets provided a compelling narrative, not because the business model had a well-defined budget owner. They bet on a growing market for cross-border medical opinions amid increasing telehealth acceptance, but the upside may be limited by competition from established players and the challenge of regulatory hurdles in different countries. The potential durability of the narrative is questionable as market saturation grows rapidly.

Source: SEC EDGAR Form D filing